- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA clears Syncor’s brachytherapy seeds
Radiopharmaceutical firm Syncor International received 510(k) clearance from the Food and Drug Administration last month for its iodine-125 seeds, the company’s first product in a line of radioactive implants for treatment of prostate cancer.
Radiopharmaceutical firm Syncor International received 510(k) clearance from the Food and Drug Administration last month for its iodine-125 seeds, the companys first product in a line of radioactive implants for treatment of prostate cancer.
Woodland Hills, CA-based Syncor began to develop the seeds seven months ago, and will market its brachytherapy seed products in the U.S. under the trade name PharmaSeed, according to Robert Funari, president and CEO. In the pipeline is a product using palladium-103, for use with more aggressive tumors.
In other Syncor news, the company plans to begin a stock repurchase program it announced in July. Syncor has 500,800 shares authorized for purchase. When it will begin buying shares and how many it will buy has not been determined.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
